Moderna Rises on Phase 3 Melanoma Data

Positive news regarding Moderna's Phase 3 melanoma data appears to have had a strong upward effect on the stock. The price has risen over 16% in 24 hours to reach 168.40 and is trading significantly above its SMA20 and SMA50. Although the RSI at 70.79 is approaching overbought territory, the MACD is above the signal line and supports positive momentum. In the short term, news-driven optimism may continue, but there is a risk that the upward movement could be limited due to overbought conditions and profit-taking. Nevertheless, the overall outlook for 1-3 days is upward.

MRK stock rose 3.56% in the last 24 hours, closing at 149.11, and its RSI14 indicator has entered overbought territory at 72.95. The MACD line is above the signal line and in positive territory, indicating strong short-term momentum. Although the news headline is not directly related to MRK, Moderna's rise on Phase 3 melanoma data, as a positive development in cancer immunotherapy, could increase optimism for the oncology sector in which MRK also operates. However, due to the RSI being at an overbought level and the news not being directly related to the company, there is a risk that the upward movement may be limited. While a slight upward trend is expected in the short term, it is also necessary to consider that profit-taking may occur.